Latest from Vanderbilt-Ingram Cancer Center

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

Eric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.

In an effort to share some of the evolving knowledge about COVID-19 and how it is impacting the healthcare system on a global scale, the Uromigos group discusses statistics, strategies, and new studies as they relate to COVID-19 and patients with genitourinary cancers.

Eric Shinohara, MD, MSCI, discusses radiation therapy considerations for patients with prostate cancer.

Sam S. Chang, MD, MBA, discusses remaining questions regarding molecular testing in prostate cancer.

We recently traveled to Nashville, Tennessee for a State of the Science Summit^™ on Genitourinary Malignancies, which featured insights from Vanderbilt-Ingram Cancer Center faculty.

Brian Rini, MD, inaugural chief of Clinical Trials at Vanderbilt-Ingram Cancer Center, discusses some of the exciting data on kidney cancer presented at the 2020 Genitourinary Cancers Symposium.

Jeremy L. Warner, MD, MS, discusses the goals of the COVID-19 and Cancer Consortium Registry, what other data need to be extrapolated with COVID-19, and how the virus could impact patients with cancer.